Sirona Biochem Financials
SBM Stock | CAD 0.07 0.01 13.33% |
Operating Margin (258.82) | Short Ratio 1.51 | Return On Equity (98.10) |
Sirona | Select Account or Indicator |
Please note, the imprecision that can be found in Sirona Biochem's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sirona Biochem Corp. Check Sirona Biochem's Beneish M Score to see the likelihood of Sirona Biochem's management manipulating its earnings.
Sirona Biochem Stock Summary
Sirona Biochem competes with Westaim Corp, Pulse Seismic, Quarterhill, and TECSYS. Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada. SIRONA BIOCHEM operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange.Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | Canada Stock View All |
Exchange | TSX Venture Exchange |
ISIN | CA82967M1005 |
Business Address | 595 Burrard Street, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.sironabiochem.com |
Phone | 604 641 4466 |
Currency | CAD - Canadian Dollar |
You should never invest in Sirona Biochem without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Sirona Stock, because this is throwing your money away. Analyzing the key information contained in Sirona Biochem's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sirona Biochem Key Financial Ratios
There are many critical financial ratios that Sirona Biochem's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Sirona Biochem Corp reports annually and quarterly.Revenue | 34.78 K | ||||
Gross Profit | 621.75 K | ||||
EBITDA | (2.26 M) | ||||
Net Income | (2.54 M) | ||||
Total Asset | 1.03 M |
Sirona Biochem Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.1M | 1.3M | 1.3M | 1.0M | 928.9K | 882.4K | |
Other Current Liab | 102.1K | 105.8K | 105.8K | 175.3K | 201.6K | 103.5K | |
Other Liab | 102.9K | 121.6K | 130.6K | 115.1K | 132.4K | 117.8K | |
Net Tangible Assets | 2.2M | 47.4K | (97.0K) | 214.5K | 193.1K | 202.7K | |
Retained Earnings | (35.5M) | (37.8M) | (41.4M) | (43.9M) | (39.5M) | (37.5M) | |
Accounts Payable | 620.5K | 297.4K | 315.6K | 1.1M | 1.3M | 1.3M | |
Cash | 1.5M | 778.0K | 421.5K | 571.5K | 657.2K | 987.0K | |
Long Term Debt | 850.4K | 468.8K | 91.1K | 1.5M | 1.8M | 1.9M | |
Net Receivables | 107.2K | 55.9K | 23.9K | 6.6K | 5.9K | 5.6K | |
Total Liab | 2.1M | 1.4M | 1.1M | 3.5M | 4.1M | 2.1M | |
Short Long Term Debt | 264.2K | 300.7K | 337.7K | 637.7K | 733.3K | 536.1K | |
Total Current Assets | 2.1M | 1.3M | 1.3M | 1.0M | 1.2M | 1.7M | |
Common Stock | 28.5M | 29.1M | 31.2M | 34.5M | 39.7M | 21.5M | |
Net Invested Capital | 1.2M | 672.5K | 643.3K | (334.3K) | (300.9K) | (285.8K) | |
Net Working Capital | 1.1M | 518.5K | 407.4K | (843.5K) | (759.2K) | (721.2K) | |
Capital Stock | 29.1M | 31.2M | 34.5M | 34.7M | 39.9M | 32.7M |
Sirona Biochem Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 13.1K | 3.3K | 27.0K | 201.7K | 231.9K | 243.5K | |
Total Revenue | 105.7K | 268.0K | 671.9K | 34.8K | 40.0K | 38.0K | |
Operating Income | (4.2M) | (2.3M) | (3.5M) | (2.4M) | (2.2M) | (2.3M) | |
Ebit | (4.2M) | (4.0M) | (2.1M) | (3.4M) | (3.1M) | (3.2M) | |
Research Development | 1.3M | 1.2M | 1.1M | 1.2M | 1.4M | 1.1M | |
Income Before Tax | (4.1M) | (2.3M) | (3.6M) | (2.5M) | (2.3M) | (2.4M) | |
Net Income | (4.1M) | (2.3M) | (3.6M) | (2.5M) | (2.3M) | (2.4M) | |
Income Tax Expense | (6.2K) | (7.1K) | (5.7K) | 6.0K | 6.8K | 8.5K | |
Net Interest Income | 27.5K | (3.3K) | (27.0K) | (201.7K) | (231.9K) | (220.3K) | |
Tax Provision | (7.1K) | (5.7K) | 6.0K | (954.0) | (858.6) | (815.67) | |
Ebitda | (4.4M) | (4.1M) | (2.3M) | (3.5M) | (3.2M) | (3.3M) |
Sirona Biochem Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (2.2M) | (757.9K) | (356.5K) | (8.0K) | (7.2K) | (6.8K) | |
Net Borrowings | (240.6K) | (133.4K) | (308.3K) | (338.4K) | (304.5K) | (289.3K) | |
Net Income | (4.1M) | (2.3M) | (3.6M) | (2.5M) | (2.3M) | (2.4M) | |
Change To Netincome | 989.6K | 1.6M | 337.1K | 1.7M | 1.9M | 2.0M | |
End Period Cash Flow | 1.5M | 778.0K | 421.5K | 571.5K | 514.3K | 826.6K | |
Free Cash Flow | (2.2M) | (2.2M) | (2.2M) | (1.8M) | (2.0M) | (2.1M) | |
Other Non Cash Items | 25.1K | 2.5K | 195.8K | 193.4K | 222.4K | 123.8K |
Sirona Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sirona Biochem's current stock value. Our valuation model uses many indicators to compare Sirona Biochem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sirona Biochem competition to find correlations between indicators driving Sirona Biochem's intrinsic value. More Info.Sirona Biochem Corp is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sirona Biochem's earnings, one of the primary drivers of an investment's value.Sirona Biochem Corp Systematic Risk
Sirona Biochem's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sirona Biochem volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Sirona Biochem Corp correlated with the market. If Beta is less than 0 Sirona Biochem generally moves in the opposite direction as compared to the market. If Sirona Biochem Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sirona Biochem Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sirona Biochem is generally in the same direction as the market. If Beta > 1 Sirona Biochem moves generally in the same direction as, but more than the movement of the benchmark.
Sirona Biochem Corp Total Assets Over Time
Sirona Biochem Thematic Clasifications
Sirona Biochem Corp is part of Iron investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Steel and Iron production. Companies involved in production of steel and iron
This theme covers Steel and Iron production. Companies involved in production of steel and iron. Get More Thematic Ideas
Iron | View |
Sirona Biochem December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sirona Biochem help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sirona Biochem Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sirona Biochem Corp based on widely used predictive technical indicators. In general, we focus on analyzing Sirona Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sirona Biochem's daily price indicators and compare them against related drivers.
Downside Deviation | 11.57 | |||
Information Ratio | 0.0413 | |||
Maximum Drawdown | 67.78 | |||
Value At Risk | (15.38) | |||
Potential Upside | 20.0 |
Additional Tools for Sirona Stock Analysis
When running Sirona Biochem's price analysis, check to measure Sirona Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sirona Biochem is operating at the current time. Most of Sirona Biochem's value examination focuses on studying past and present price action to predict the probability of Sirona Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sirona Biochem's price. Additionally, you may evaluate how the addition of Sirona Biochem to your portfolios can decrease your overall portfolio volatility.